• About us
• Contact

Advertisement

Organisation › Details

Albireo Pharma Inc. (Nasdaq: ALBO)

Albireo Pharma, Inc. (NASDAQ:ALBO), is a clinical-stage company focused on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in phase 2 of development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo's pipeline includes assets in phase 3 for chronic constipation, phase 2 for bile acid malabsorption and pre-clinical development for NASH. Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden. *

 

	Start	2020-07-11 existent
	Group	Ipsen (Group)
	Industry	DRUGS, ORPHAN
	Industry 2	Bylvay®
	Person	Cooper, Ron (Albireo 202007)
	Region	Boston, MA
	Country	United States (USA)
	City	n. a. Boston, MA
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Ipsen (Group)

• [1] Ipsen S.A.. (1/9/23). "Press Release: Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases". Paris & Boston, MA....
• [2] Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA....
• [3] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
• [4] Synthace Ltd.. (8/2/21). "Press Release: Synthace Unveils First Life Sciences R&D Cloud Addressing Complexity, Speed & Reproducibility for Scientists". London....
• [5] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
• [6] Ipsen S.A.. (1/24/20). "Press Release: Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria". Paris....
• [7] Ipsen S.A.. (12/18/19). "Press Release: Ipsen Announces Departure of David Meek as Chief Executive Officer". Paris....
• [8] Ferring Pharmaceuticals S.A.. (12/18/19). "Press Release: FerGene Appoints David Meek Chief Executive Officer". Cambridge, MA....
• [9] Lysogene S.A.. (10/17/19). "Press Release: Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer". Paris....
• [10] Genmab A/S. (3/11/19). "Press Release: Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.